News

A team of economists and oncologists led by Analysis Group Managing Principal Eric Q. Wu, Ph.D., and Harvard University’s Dana-Farber Cancer Institute oncologist James D. Griffin, M.D., found that patients with chronic myeloid leukemia (CML) who were treated with nilotinib are associated with better treatment adherence, fewer hospitalizations, and lower total health care costs than patients treated with dasatinib. The team, which also included Analysis Group Senior Economist Annie Guerin and Manager Andrew P. Yu, along with Novartis Pharmaceuticals’ Vamsi K. Bollu, and Amy Guo, analyzed patients who were diagnosed with CML and treated with a second-line tyrosine kinase inhibitor (TKI) in a second-line real-world setting. Patients were followed for up to six months from the initiation of treatment to the end of data availability. Treatment adherence, medical visits (including outpatient visits and hospitalization days), and health care costs were compared between the two TKIs. The study, among the first to provide information on real-world treatment outcomes associated with the use of nilotinib and dasatinib, will be published in Current Medical and Research Opinion. It was also the subject of Dr. Wu’s presentation and video interview at the Annual American Society of Hematology Meeting on December 6, 2010.

Read the press release  

View additional information